A group of federal lawmakers seeks to remove regulatory barriers that inhibit psychedelics in research and compassionate use cases. Senators Cory Booker (D-N.J.) and Rand Paul (R-KY) introduced an updated version of the Breakthrough Therapies Act to the Senate. If passed, the bill would make it easier to use Schedule 1 drugs with a breakthrough therapy designation. Specifically, it would allow drugs, including MDMA and psilocybin, which have the breakthrough designation, to be transferred from a Schedule I to Schedule II drug, enabling more patient access and more clinical investigation.
Read the full article: A Group of Lawmakers Want to Make It Easier for Psychedelic Research, Compassionate Use //
Source: https://bhbusiness.com/2023/03/10/a-group-of-lawmakers-want-to-make-it-easier-to-use-psychedelics-for-research-compassionate-use-cases